SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back

National Association for Continuing Education
Sandhya Khurana, MD
Associate Professor, Pulmonary and Critical Care Medicine
Co-Director, Mary Parkes Center for Asthma, Allergy & Pulmonary Care
University of Rochester School of Medicine
Rochester, NY

David Lederer, MD, MS
Associate Professor of Medicine
Co-Director, Interstitial Lung Disease Program
Columbia University Medical Center
New York, NY"

Course Director
Fernando Martinez, MD, MS
Professor of Medicine
Weill Cornell Medical College
New York-Presbyterian Hospital/Weill Cornell Medical Center,
New York, NY

: The Role of Biologic Therapy in Severe Asthma: A Shifting Treatment Paradigm
Activity/Course #:
: NCME380
: Free
Release/Start Date:
: Jun 01 2019
Expiration Date:
: May 31 2020
: Pulmonology
Target Audience:
: Pulmonologists, Primary Care Physicians, Nurse Practitioners, Physician Assistants
: Webcast
Estimated Time To Complete CME Activity:
: 1.0 Hour
: 1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s) which includes 0.75 pharmacology hour(s)
Hardware/Software Requirements:
Program Summary
Asthma is a heterogenous disorder usually characterized by chronic airway inflammation, and defined by respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough that vary over time and in intensity, together with variable expiratory airflow limitation. The disorder that affects 18.7 million adults and 7 million children in the United States. This activity will examine the current concepts in the pathophysiology of asthma and type 2 inflammation, discuss the clinical assessment of asthma control and risk factors for poor asthma outcomes, how to individualize treatment and recognize appropriate candidates for biologicals, and the impact of comorbid conditions.

This webcast was recorded live at the Conversations in Pulmonology 2019 Live Virtual Broadcast and is being used with the permission of the presenters.

Learning Objectives
After completing this program participants should be able to:
  1. Describe the current concepts in the pathophysiology of asthma and type 2 inflammation, and the implications of biologic therapies in the era of precision medicine
  2. Discuss the clinical assessment of asthma control and risk factors for poor asthma outcomes
  3. Individualize the treatment approach for patients with moderate to severe asthma while recognizing appropriate candidates for biologicals and other advanced therapies
  4. Recognize the impact of comorbid conditions on asthma control and evidence-based approaches to their treatment

 How to obtain the CME Certificate

  1. Register for the course at
  2. View the content.
  3. Complete and submit the post-test and evaluation.
  4. A minimum passing score of 60% must be earned on the post-test in order to complete the CME activity.
  5. Print your CME certificate
Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education which includes 0.75 pharmacology hours.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the the accredited providers to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.

Dr. Khurana has served as a Principal Investigator for GlaxoSmithKline and Sanofi.

Dr. Lederer is a consultant for Veracyte, Inc, Pliant Therapeutics, Inc, Bristol-Myers Squibb Company, Galecto Biotech, Galapagos NV, F. Hoffmann-La Roche AG, and Boehringer Ingelheim.

Course Director
Dr. Martinez is a Consultant and a Steering Committee Member of AstraZeneca, GlaskoSmithKline, Boehringer Ingelheim, Genetech, RespiVert, Ltd, Sunovian, Teva and Veracyte.

Activity Planning Committe
Gregg Sherman, MD, has no relationships to disclose.

Josh Kilbridge, Medical Writer, has no relationships to disclose.

Michelle Frisch, MPH, has no relationships to disclose.

Daniela Hiedra, BA, has no relationships to disclose.

Sandy Bihlmeyer, MEd, has no relationships to disclose.

Alan Goodstat, LCSW, has no relationships to disclose.

Diego Maselli, MD serves as a consultant for Novartis, Sanofi Regeneron, AstraZeneca and GlaxoSmithKline. He is also a speaker for Sanofi Regeneron, Sunovion and GlaxoSmithKline.
Commercial Support
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.